Type 2 CRSwNP is linked to worse health-related quality of life, with higher rates of smell loss and rhinorrhea emerging as ...

French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST ...

In the EVEREST trial, 360 adults with severe, uncontrolled CRSwNP and coexisting asthma were randomized to receive Dupixent 300 mg (n=181) every two weeks or a weight- and immunoglobulin E (IgE ...

Dupixent demonstrated superior efficacy in reducing nasal polyp size and improving smell in CRSwNP, as well as enhancing lung function and disease control in asthma, with benefits observed as ...

According to the ACTIONS study, 39% of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) faced overexposure to ...

Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe ...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed ...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair ...

The company is progressing with multiple Phase 2 trials for its investigational treatment targeting severe respiratory ...

According to the ACTIONS study, 39% of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) faced overexposure to oral corticosteroids (OCS) before beginning biologic therapy.

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...